Expansion of the Medical Supply Business and SPD Outsourcing Contracts
First written in FY2016. 24 of 38 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-10-20.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In addition to new SPD facilities under contract beginning operations in the first half, bundled-contract SPD projects with multiple hospitals under different operating entities commenced, contributing to revenue growth. Furthermore, progress in improving management efficiency following the integration of 5 companies effective 1 October 2024, together with the launch of a new medical supplies logistics hub in the Tokyo metropolitan area, strengthened the business foundation.」
Operations progressed at new SPD facilities, bundled-contract projects with multiple hospitals under different operating entities commenced, and the Tokyo metropolitan logistics hub began operating, expanding the business foundation and revenue. - FY2026-H1AdvancedAnnual report
「In the Medical Supply business, the performance of the SPD facilities that began operating in the previous fiscal year remained firm, and bundled-contract SPD projects with multiple hospitals under different operating entities also commenced.」
In addition to the continued operation of existing SPD facilities, bundled-contract SPD projects with multiple hospitals under different operating entities commenced. Revenue was ¥246,756 million and segment profit was ¥2,835 million, representing increases of 8.7% and 11.8%, respectively, from the interim period of the previous year. - FY2025AdvancedAnnual report
「Revenue and profit increased as multiple new large-scale SPD facilities began operations ahead of the initial plan, and the results of the orthopedic dealer that joined the group in the fourth quarter of the previous fiscal year contributed for the full year.」
Multiple new large-scale SPD facilities began operations ahead of the initial plan, and the Medical Supply business recorded revenue of ¥474,919 million and segment profit of ¥6,970 million. - FY2025-H1AdvancedAnnual report
「In the Medical Supply business, revenue increased as multiple new large-scale SPD facilities began operations, but profit declined due in part to the recording of initial expenses, including labor and equipment costs associated with their launch. As a result, revenue was ¥227,091 million, up 10.3% from the previous interim consolidated accounting period, and segment profit (operating profit) was ¥2,536 million, down 9.4%.」
Multiple new large-scale SPD facilities began operations, and revenue increased 10.3% year on year. Profit declined 9.4% year on year due to the upfront recording of labor and equipment costs associated with their launch. - FY2024-Q3RestatedAnnual report
「The new SPD facilities contracted in the second half of the previous year operated solidly.」
The new SPD facilities contracted in the second half of the previous year operated solidly, and measures to expand existing SPD contracts are continuing. - FY2024-Q2RestatedAnnual report
「In the Medical Supply business, demand for medical supplies recovered as the number of surgical cases increased, among other factors, despite the impact of higher raw material prices and labor costs.」
The disclosure states that demand for medical supplies recovered as the number of surgical cases increased despite the impact of higher costs. No new milestone, such as a new SPD facility, was indicated. - FY2024-Q1RestatedAnnual report
「In the Medical Supply business, demand for medical supplies recovered as the number of surgical cases increased, among other factors, despite the impact of higher raw material prices and logistics costs.」
The disclosure states that demand for medical supplies recovered as the number of surgical cases increased, despite higher raw material and logistics costs. No new milestone, such as an SPD contract, was indicated. - FY2023-Q2RestatedAnnual report
「In the Medical Supply business, projects funded by infectious disease control subsidies and similar programs declined, but demand for medical supplies recovered as new SPD facilities progressed smoothly and the number of surgical cases increased, among other factors.」
New SPD facilities operated smoothly, and demand for medical supplies recovered as the number of surgical cases increased. No milestone such as the opening of a new facility was indicated. - FY2023-Q1AdvancedAnnual report
「In the Medical Supply business, demand for medical supplies recovered as the number of surgical cases increased, among other factors. However, initial expenses associated with the launch of new SPD facilities were recorded, while projects funded by infectious disease control subsidies and similar programs declined.」
New SPD facilities entered the operating stage, and demand for medical supplies was shown to be recovering. At the same time, initial expenses associated with their launch were recorded. - FY2022RestatedAnnual report
「In the Medical Supply business, while medical institutions continued to face restrictions on medical services, contracts for SPD services continued to expand, and the new medical supply logistics center, the Osaka Solution Center, began full-scale operations.」
The expansion of SPD contracts and the start of full-scale operations at the Osaka Solution Center were confirmed as business infrastructure-strengthening measures continuing from the previous fiscal year. - FY2022-Q2RestatedAnnual report
「The automated warehouse for medical supplies, the Osaka Solution Center, began full-scale operations, establishing an efficient management and operating structure.」
It was reconfirmed that an efficient management and operating structure for medical supplies has been established at the Osaka Solution Center, which began full-scale operations in the previous quarter. - FY2022-Q1AdvancedAnnual report
「In addition, the Osaka Solution Center, an industry-first automated warehouse that centrally manages all consumables inventory using RFID, began full-scale operations.」
The Osaka Solution Center, completed in the previous fiscal year and prepared for full-scale operations, progressed to the stage of commencing full-scale operations. - FY2021RestatedAnnual report
「In addition, the Osaka Solution Center, an industry-first automated warehouse, was completed.」
The completion of the Osaka Solution Center was confirmed in the annual report as a measure to improve SPD facility operations and logistics efficiency. - FY2021-Q3AdvancedAnnual report
「In the Medical Supply business, the Osaka Solution Center, an industry-first automated warehouse that centrally manages all consumables inventory using RFID, was completed, and preparations progressed smoothly toward full-scale operations in June 2021.」
The automated warehouse that centrally manages all consumables inventory using RFID was completed, and preparations advanced toward full-scale operations in June 2021. Specific milestones were provided for improving operational efficiency and strengthening the infrastructure of the Medical Supply business. - FY2021-Q2RestatedAnnual report
「In the Medical Supply business, results remained solid through collaboration within the group and management efficiency improvements despite the impact of reimbursement price revisions. However, the results continued to reflect the temporary decline in demand for medical supplies caused by reduced medical consultations and fewer surgeries following the spread of COVID-19 at the beginning of the period. As a result, revenue was ¥154,636 million, down 3.7% from the same period of the previous year on a consolidated cumulative basis, and segment profit (operating profit) was ¥2,308 million, down 6.0%.」
While collaboration within the group and management efficiency improvements continued, the impact of the temporary decline in demand for medical supplies caused by COVID-19 remained, and revenue and segment profit were below the previous year's levels. - FY2021-Q1RestatedAnnual report
「In the Medical Supply business, securing profit remained difficult due to the impact of reimbursement price revisions, but operations generally proceeded as planned through collaboration within the group and greater operating efficiency. As a result, revenue was ¥74,275 million, down 2.1% from the same period of the previous year on a consolidated cumulative basis, while segment profit (operating profit) was ¥850 million, up 8.0%.」
Despite continued earnings pressure from reimbursement price revisions, operations generally proceeded as planned through collaboration within the group and greater operating efficiency, and segment profit increased 8.0% year on year. No new milestone, such as acquiring a contract for a new SPD facility, was indicated, so this was treated as a reaffirmation of existing measures. - FY2020AdvancedAnnual report
「In the Medical Supply business, results progressed solidly as the company worked to acquire new projects, mainly involving specialized materials, and improve the operating efficiency of SPD facilities. As a result, revenue was ¥325,664 million, up 12.2% from the previous consolidated fiscal year, and segment profit (operating profit) was ¥5,035 million, up 20.1%.」
Through the acquisition of new projects involving specialized materials and more efficient operation of SPD facilities, revenue was ¥325,664 million and segment profit was ¥5,035 million, with profit increasing 20.1% year on year. - FY2020-Q3AdvancedAnnual report
「In the Medical Supply business, results remained solid as the company worked to acquire new projects and improve the operating efficiency of SPD facilities. As a result, revenue was ¥241,359 million, up 11.9% from the same period of the previous year on a consolidated cumulative basis, and segment profit (operating profit) was ¥3,546 million, up 13.9%.」
The acquisition of new projects and more efficient operation of SPD facilities were identified as specific measures, with progress quantified through increases in revenue and segment profit. - FY2020-Q2AdvancedAnnual report
「The Medical Supply business performed steadily through collaboration with the Total Pack Produce business, the acquisition of contracts for new SPD facilities, and more efficient operation of SPD facilities. There was also front-loaded demand for consumables ahead of the consumption tax increase. As a result, revenue was ¥160,607 million, up 16.8% from the cumulative second quarter of the previous consolidated fiscal year, and segment profit (operating profit) was ¥2,455 million, up 43.3%.」
The acquisition of contracts for new SPD facilities and more efficient operation of SPD facilities are explicitly stated, with specific progress shown by increases in revenue and segment profit. - FY2020-Q1RestatedAnnual report
「In the Medical Supply business, securing profit remained difficult due to the impact of last year's reimbursement price revision, but operations generally proceeded as planned through collaboration within the group and greater operating efficiency. As a result, revenue was ¥75,882 million, up 11.5% from the same period of the previous year on a consolidated cumulative basis, and segment profit (operating profit) was ¥788 million, up 11.9%.」
Despite continued profit pressure from reimbursement price revisions, operations generally proceeded as planned through collaboration within the group and greater operating efficiency, with revenue and segment profit increasing. - FY2019-Q3AdvancedAnnual report
「In the Medical Supply business, securing profit from sales of specified insured medical materials remained difficult due to the impact of reimbursement price revisions, but operations progressed generally as planned through measures including more efficient SPD facility operations. As a result, revenue was ¥215,681 million, up 7.7% from the same period of the previous year on a consolidated cumulative basis, and segment profit (operating profit) was ¥3,112 million, up 15.2%.」
Operations progressed generally as planned through more efficient SPD facility operations, and segment profit increased 15.2% year on year. - FY2019-Q2RestatedAnnual report
「In the Medical Supply business, operations progressed generally as planned, due in part to the smooth launch of new SPD facilities in the previous fiscal year. As a result, revenue was ¥137,553 million, up 6.0% from the same period of the previous year on a consolidated cumulative basis, and segment profit (operating profit) was ¥1,713 million, up 8.5%.」
The new SPD facilities launched in the previous fiscal year operated smoothly, and the Medical Supply business progressed generally as planned. Revenue and segment profit also increased, but no specific milestone such as the launch of a new facility was stated. - FY2019-Q1RestatedAnnual report
「In the Medical Supply business, operations progressed generally as planned, including the smooth launch of new SPD facilities in the previous fiscal year. As a result, revenue was ¥68,078 million, up 7.5% from the same period of the previous year on a consolidated cumulative basis, and segment profit (operating profit) was ¥704 million, up 2.9%.」
The new SPD facilities launched in the previous fiscal year operated smoothly, and the Medical Supply business was described as progressing generally as planned. - FY2018AdvancedAnnual report
「In the Medical Supply business, results remained solid as the launch of new SPD facilities in the previous fiscal year progressed smoothly and demand for equipment replacement recovered in the second half, among other factors. As a result, revenue was ¥274,058 million, up 4.0% from the previous consolidated fiscal year, and segment profit (operating profit) was ¥4,161 million, up 25.4%.」
The launch of new SPD facilities progressed, and the recovery in demand for equipment replacement contributed to a 25.4% year-on-year increase in segment profit. - FY2018-Q3AdvancedAnnual report
「In the Medical Supply business, the impact of advisory fees associated with the large-scale M&A recorded in the previous fiscal year ended. In addition, operations at the SPD facilities for which contracts were concentrated last year improved and proceeded smoothly, among other factors, resulting in higher revenue and profit. As a result, revenue was ¥200,175 million, up 4.4% from the same period of the previous year on a consolidated cumulative basis, and segment profit (operating profit) was ¥2,701 million, up 50.9%.」
The impact of one-time expenses associated with the large-scale M&A ended, and improvements in the operation and smooth running of SPD facilities resulted in segment profit increasing 50.9% year on year. - FY2018-Q2AdvancedAnnual report
「In the Medical Supply business, the impact of advisory fees associated with the large-scale M&A recorded in the previous fiscal year ended, while operations at the SPD facilities for which contracts were concentrated last year improved and proceeded smoothly, among other factors, resulting in higher revenue and profit. As a result, revenue was ¥129,756 million, up 2.2% from the same period of the previous year on a consolidated cumulative basis, and segment profit (operating profit) was ¥1,578 million, up 49.2%.」
The impact of one-time expenses associated with the large-scale M&A ended, and improvements in the operation and smooth running of SPD facilities resulted in segment profit increasing 49.2% year on year. - FY2018-Q1AdvancedAnnual report
「In the Medical Supply business, the impact of advisory fees associated with the business integration with Konishi Kyowa Holdings Co., Ltd., which had been recorded in the previous fiscal year, ended, and SPD facilities for which contracts were concentrated last year began operating smoothly, among other factors, resulting in higher profit. As a result, revenue was ¥63,335 million, up 0.8% from the same period of the previous year on a consolidated cumulative basis, and segment profit (operating profit) was ¥684 million, up 134.0%.」
The impact of one-time expenses associated with the business integration ended, and the SPD facilities for which contracts were concentrated in the previous year operated smoothly, resulting in segment profit increasing 134.0% year on year. - FY2017-Q3RestatedAnnual report
「In the Medical Supply business, revenue and profit increased following the business integration with Konishi Kyowa Holdings Co., Ltd. However, the profit margin remained low due to temporary increases in costs associated with taking on a new large-scale SPD facility and intensifying competition following the reimbursement price revision. As a result, revenue was ¥191,695 million, up 69.3% from the same period of the previous year on a consolidated cumulative basis, and segment profit (operating profit) was ¥1,790 million, up 17.4%.」
While the business continued to expand through the business integration and the acquisition of contracts for new large-scale SPD facilities, the profit margin remained low due to initial contract costs and intensifying competition. - FY2017-Q2AdvancedAnnual report
「In the Medical Supply business, despite the impact of revisions to reimbursement prices, revenue increased substantially due to the business integration with Konishi Kyowa Holdings Co., Ltd. and the acquisition of contracts to operate new SPD facilities. As a result, revenue was ¥126,992 million, up 77.1% from the same period of the previous year on a consolidated cumulative basis.」
In addition to the business integration, contracts to operate new SPD facilities progressed, with the resulting revenue growth in the Medical Supply business shown in specific figures. - FY2017-Q1AdvancedAnnual report
「In the Medical Supply business, revenue increased substantially following the business integration with Konishi Kyowa Holdings Co., Ltd.」
Following the consolidation effect of the business integration, revenue in the Medical Supply business was ¥62,834 million, up 82.2% year on year. - FY2016First statedAnnual report
「Revenue and profit increased as the results of the orthopedic company acquired through M&A contributed and the number of facilities newly outsourcing SPD operations increased.」
The Medical Supply business is being expanded through acquisitions and new SPD contracts. The acquisition of Nishino Medical Instruments was also intended to expand the scale of this business.